Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Results
05/07/2008
Contacts
For Interleukin Genetics: Investors: Media:
Eliot M. Lurier Melanie Friedman Catherine Cloft
(781) 398-0700 Stern Investor Relations LaVoie Group
(212) 362-1200 (978) 745-4200 x107
Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
WALTHAM, MA – May 7, 2008 – Interleukin Genetics, Inc. (AMEX: ILI), announced today that it will host a conference call and webcast on Wednesday, May 14, 2008 at 4:30 p.m. ET to review the Company’s first quarter 2008 financial results and provide an update on recent corporate developments.
To access the live call, dial 877-627-6555 (domestic) or 719-325-4869 (international). The live webcast will be available on the Investors section of the Company’s website, www.ilgenetics.com.
Replay access of the teleconference will be available for one week following the call by dialing 888-203-1112 (domestic) or 719-457-0820 (international). The passcode for the replay is 4243283. The webcast will be archived following the call at www.ilgenetics.com.
About Interleukin Genetics
Interleukin Genetics, Inc. (AMEX: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals®, including Ginkoba®, Ginsana® and Venastat® which are sold at the nation’s largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit www.ilgenetics.com.
###